ROIV Stock Forecast: Roivant Sciences Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$39
−0.80% on the day

The 13 Wall Street analysts covering Roivant Sciences Ltd. hold a median 12-month price target of $51 — +32.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 83 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$28.0B
Ticker Nerd rank
83/ 100
Median analyst target
$51
Analysts covering
13
Revenue$1.4M−33.5% y/y
Operating income−$366.4M
Net income−$290.6M
Free cash flow−$270.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.2%
1M
+10.7%
YTD
+78.1%
1Y
+90.7%
From 52W high
−7.6%
From 52W low
+92.3%
$20
$42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Roivant Sciences Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
83/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Volatility
94
Revisions
91
Growth
81
Accruals
59
Value
59
Issuance
58
Quality
35

Momentum (99): The shares have been drifting up relative to others.

Quality (35): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ROIV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ROIV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ROIVHigh $62Median $51Low $42

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
11
Buy
2
Hold
0
Sell
$42
Low
$51
Median
$62
High

The green dot is the last close — the median target sits +32.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 13 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Nov 2026GuggenheimMaintainsBuy$46 → $48
10 Nov 2026HC Wainwright & Co.MaintainsBuy$47 → $48
28 Oct 2026CitigroupMaintainsBuy$46 → $56
12 Oct 2026Wolfe ResearchDowngradePeer Perform—
17 Sept 2026StifelInitiatesBuy$51
9 Sept 2026GuggenheimMaintainsBuy$42 → $46
9 Sept 2026TD CowenMaintainsBuy$50 → $55
8 Sept 2026HC Wainwright & Co.MaintainsBuy$41 → $47
8 Sept 2026JefferiesMaintainsBuy$42 → $52
28 Aug 2026HC Wainwright & Co.ReiteratesBuy$41
10 Aug 2026CitigroupMaintainsBuy$42 → $46
7 Aug 2026GuggenheimMaintainsBuy$36 → $42
7 Aug 2026HC Wainwright & Co.MaintainsBuy$34 → $41
26 May 2026GuggenheimMaintainsBuy$30 → $36
21 May 2026CitigroupMaintainsBuy$35 → $42
21 May 2026HC Wainwright & Co.ReiteratesBuy$34
21 May 2026TD CowenMaintainsBuy$38 → $41
16 Apr 2026Piper SandlerMaintainsOverweight—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Feb 2026CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ROIV.

Market Radar

This page is one stock. Monday covers all of them.

ROIV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ROIV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Roivant Sciences Ltd. returned +90.7% against +6.9% for the S&P 500, dividends included.

ROIV vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Jan 26Apr 26Jul 26Oct 26ROIVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ROIV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
681.8×

Cheaper than 1% of US stocks

Price / book
7.0×

Cheaper than 12% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
80.3%

Higher than 91% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−8.5%

Higher than 37% of US stocks

Return on assets
−16.5%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Roivant Sciences Ltd. has a market value of $28.0B and an enterprise value of $24.5B.

  • Revenue in the twelve months to 30 June 2026: $7.5M. The latest quarter shrank 33.5% year on year.

  • Net income over the same four quarters: −$414.6M, a −5504.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.53.

  • Free cash flow in the twelve months to 30 June 2026: −$821.1M.

  • Roivant Sciences Ltd. spent $317.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 722.7M.

  • Roivant Sciences Ltd. employs 721 people — $10K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ROIV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ROIVRoivant Sciences Ltd.$28.0B83
INSMInsmed, Inc.$30.9B76
INCYIncyte Corp.$22.9B89
RVMDRevolution Medicines, Inc.$33.6B56
RPRXRoyalty Pharma Plc$39.4B97
ALNYAlnylam Pharmaceuticals, Inc.$19.3B58
ASNDAscendis Pharma A/S$16.6B93

Take a look at ROIV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Roivant Sciences Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ROIV

What is the ROIV stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Roivant Sciences Ltd. have a median 12-month price target of $51, with estimates ranging from $42 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ROIV stock a buy right now?

Of the 13 analysts covering Roivant Sciences Ltd., 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Roivant Sciences Ltd. 83 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ROIV?

As at 21 Nov 2026, Roivant Sciences Ltd. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will ROIV stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +32.0% from the last close, and Ticker Nerd's factor model ranks Roivant Sciences Ltd. 83 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ROIV stock forecast for 2030?

No analyst covering Roivant Sciences Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ROIV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $62 over the next 12 months.

How has ROIV stock performed over the past year?

Roivant Sciences Ltd. returned +90.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Roivant Sciences Ltd. do?

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates.

Company

About Roivant Sciences Ltd.

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.

CEO Mr. Matthew Gline · 721 employees · United Kingdom · https://roivant.com